These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22542415)

  • 1. [Treatment of latent tuberculosis infection].
    Fraisse P;
    Rev Mal Respir; 2012 Apr; 29(4):579-600. PubMed ID: 22542415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
    Esfahani K; Aspler A; Menzies D; Schwartzman K
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1340-6. PubMed ID: 22283892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM; Clotet L; Ferrer A; Sala MR; Garrido P; Salleras L; Domínguez A
    Respir Med; 2013 May; 107(5):768-77. PubMed ID: 23490222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of treating latent tuberculous infection: a step towards elimination?
    Diel R; Loddenkemper R; Sotgiu G; Migliori GB
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1515. PubMed ID: 24200259
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT; McBryde ES; Eisen D; Street A; Matchett E; Chen C; Shultz TR; Biggs B; Leder K
    Intern Med J; 2017 Dec; 47(12):1433-1436. PubMed ID: 29224209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the impact of patient self-selection on the costs to treat latent tuberculosis infection (LTBI) with isoniazid and transitional rifampin.
    Fluegge KR
    J Eval Clin Pract; 2014 Oct; 20(5):685-91. PubMed ID: 25087583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is isoniazid for 6 months more cost-effective than isoniazid for 9 months?
    Pina JM; Clotet L; Sala MR; Ferrer A; Arias C; Domínguez A
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):768-73. PubMed ID: 22508169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifampicin plus isoniazid for the prevention of tuberculosis in an immigrant population.
    Jiménez-Fuentes MA; de Souza-Galvao ML; Mila Augé C; Solsona Peiró J; Altet-Gómez MN
    Int J Tuberc Lung Dis; 2013 Mar; 17(3):326-32. PubMed ID: 23407221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Question 1: what are the options for treating latent TB infection in children?
    Gwee A; Coghlan B; Curtis N
    Arch Dis Child; 2013 Jun; 98(6):468-74. PubMed ID: 23661667
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.
    Shepardson D; Marks SM; Chesson H; Kerrigan A; Holland DP; Scott N; Tian X; Borisov AS; Shang N; Heilig CM; Sterling TR; Villarino ME; Mac Kenzie WR
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1531-7. PubMed ID: 24200264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment.
    Trajman A; Long R; Zylberberg D; Dion MJ; Al-Otaibi B; Menzies D
    Int J Tuberc Lung Dis; 2010 May; 14(5):551-9. PubMed ID: 20392347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.
    Young H; Wessolossky M; Ellis J; Kaminski M; Daly JS
    Clin Infect Dis; 2009 Aug; 49(3):424-7. PubMed ID: 19548835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB.
    Aspler A; Long R; Trajman A; Dion MJ; Khan K; Schwartzman K; Menzies D
    Thorax; 2010 Jul; 65(7):582-7. PubMed ID: 20627913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
    Ziakas PD; Mylonakis E
    Clin Infect Dis; 2009 Dec; 49(12):1883-9. PubMed ID: 19911936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Latent Tuberculosis Infection.
    Haley CA
    Microbiol Spectr; 2017 Apr; 5(2):. PubMed ID: 28409555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of rifampin monotherapy for latent tuberculosis infection in children.
    Daskalaki I; Byun J; Dogbey MC; Tolbert-Warren C; Watson BM
    Pediatr Infect Dis J; 2011 Nov; 30(11):1014-5. PubMed ID: 21997666
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.
    Shepardson D; MacKenzie WR
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):751. PubMed ID: 24903950
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
    Page KR; Sifakis F; Montes de Oca R; Cronin WA; Doherty MC; Federline L; Bur S; Walsh T; Karney W; Milman J; Baruch N; Adelakun A; Dorman SE
    Arch Intern Med; 2006 Sep; 166(17):1863-70. PubMed ID: 17000943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health System Costs of Treating Latent Tuberculosis Infection With Four Months of Rifampin Versus Nine Months of Isoniazid in Different Settings.
    Bastos ML; Campbell JR; Oxlade O; Adjobimey M; Trajman A; Ruslami R; Kim HJ; Baah JO; Toelle BG; Long R; Hoeppner V; Elwood K; Al-Jahdali H; Apriani L; Benedetti A; Schwartzman K; Menzies D
    Ann Intern Med; 2020 Aug; 173(3):169-178. PubMed ID: 32539440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.